Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express programmed death ligand 1 (PD-L1). METHODS: In this open-label, phase 3 trial, we randomly assigned 305 patients who had previously untreated advanced NSCLC with PD-L1 expression on at least 50% of tumor cells and no sensitizing mutation of the epidermal growth factor receptor gene or translocation of the anaplastic lymphoma kinase gene to receive either pembrolizumab (at a fixed dose of 200 mg every 3 weeks) or the investigator's choice of platinum-based chemotherapy. Crossover from the chemotherapy group to the pembrolizumab group was permitted in the event of disease progression. The primary end point, progression-free survival, was assessed by means of blinded, independent, central radiologic review. Secondary end points were overall survival, objective response rate, and safety. RESULTS: Median progression-free survival was 10.3 months (95% confidence interval [CI], 6.7 to not reached) in the pembrolizumab group versus 6.0 months (95% CI, 4.2 to 6.2) in the chemotherapy group (hazard ratio for disease progression or death, 0.50; 95% CI, 0.37 to 0.68; P<0.001). The estimated rate of overall survival at 6 months was 80.2% in the pembrolizumab group versus 72.4% in the chemotherapy group (hazard ratio for death, 0.60; 95% CI, 0.41 to 0.89; P=0.005). The response rate was higher in the pembrolizumab group than in the chemotherapy group (44.8% vs. 27.8%), the median duration of response was longer (not reached [range, 1.9+ to 14.5+ months] vs. 6.3 months [range, 2.1+ to 12.6+]), and treatment-related adverse events of any grade were less frequent (occurring in 73.4% vs. 90.0% of patients), as were grade 3, 4, or 5 treatment-related adverse events (26.6% vs. 53.3%). CONCLUSIONS: In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival and with fewer adverse events than was platinum-based chemotherapy. (Funded by Merck; KEYNOTE-024 ClinicalTrials.gov number, NCT02142738 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, ICIs are also associated with frequent and potentially organ- or life-threatening immune-related adverse events (irAEs), which generally mimic autoimmune or inflammatory conditions”
From Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database (2020) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“indeed, up to 90% of patients treated with ipilimumab and up to 70% of those treated with PD-1/PD-L1 antibodies experience at least one irAE).3,4”
From Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database (2020) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Initial trials on anti-PD-1 and anti-PD-L1 inhibitors reported a significant association between pre-treatment intratumoral PD-L1 expression and response to treatment in a variety of tumor types including melanoma and NSCLC”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Reck et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“At present, antibodies blocking PD-1 or its ligand PD-L1 have been approved to treat various solid and hematologic malignancies (Table 1) [7–12].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Response rates range from 15 to 30% (in most solid tumors) to 45–60% (in melanoma and MSI-H tumors).”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [6]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationImproved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Self-citationPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Research works printed but not linked: 1
- Xiao HQ, 2016, Onco Targets Ther, 9, 1471
Cited by
Items 401–500 of 1,054
Chen, J., Tan, Y., Sun, F., Hou, L., Zhang, C., Ge, T., Yu, H., Wu, C., Zhu, Y., Duan, L., et al. (2020) · Genome Biology · doi:10.1186/s13059-020-02064-6 · Cited by 216
Drug resistance to targeted therapeutic strategies in non-small cell lung cancer
Liu, W.-J., Du, Y., Wen, R., Yang, M., & Xu, J. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107438 · Cited by 216
Wang, D. Y., Ye, F., Zhao, S., & Johnson, D. B. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1344805 · Cited by 216
Hwang, S., Kwon, A.-Y., Jeong, J.-Y., Kim, S., Kang, H., Park, J., Kim, J.-H., Han, O. J., Lim, S. M., & An, H. J. (2020) · Scientific Reports · doi:10.1038/s41598-019-57218-9 · Cited by 215
Garassino, M. C., Gadgeel, S., Esteban, E., Felip, E., Speranza, G., Domine, M., Hochmair, M. J., Powell, S., Cheng, S. Y.-S., Bischoff, H. G., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30801-0 · Cited by 215
Self-citationMulticenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer
Adam, J., Le Stang, N., Rouquette, I., Cazes, A., Badoual, C., Pinot-Roussel, H., Tixier, L., Danel, C., Damiola, F., Damotte, D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy014 · Cited by 215
Dudnik, E., Peled, N., Nechushtan, H., Wollner, M., Onn, A., Agbarya, A., Moskovitz, M., Keren, S., Popovits-Hadari, N., Urban, D., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.024 · Cited by 215
Self-citationSchvartsman, G., Peng, S. A., Bis, G., Lee, J. J., Benveniste, M. F. K., Zhang, J., Roarty, E. B., Lacerda, L., Swisher, S., Heymach, J. V., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.07.034 · Cited by 215
Feng, B., Niu, Z., Hou, B., Zhou, L., Li, Y., & Yu, H. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201906605 · Cited by 215
Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives
Birzu, C., French, P., Caccese, M., Cerretti, G., Idbaih, A., Zagonel, V., & Lombardi, G. (2020) · Cancers · doi:10.3390/cancers13010047 · Cited by 214
Tada, Y., Togashi, Y., Kotani, D., Kuwata, T., Sato, E., Kawazoe, A., Doi, T., Wada, H., Nishikawa, H., & Shitara, K. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0403-1 · Cited by 214
Buchwald, Z. S., Wynne, J., Nasti, T. H., Zhu, S., Mourad, W. F., Yan, W., Gupta, S., Khleif, S. N., & Khan, M. K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00612 · Cited by 213
Cook, M. R., & Kim, C. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.6737 · Cited by 213
Zemek, R. M., De Jong, E., Chin, W. L., Schuster, I. S., Fear, V. S., Casey, T. H., Forbes, C., Dart, S. J., Leslie, C., Zaitouny, A., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav7816 · Cited by 212
Jassem, J., de Marinis, F., Giaccone, G., Vergnenegre, A., Barrios, C. H., Morise, M., Felip, E., Oprean, C., Kim, Y.-C., Andric, Z., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.06.019 · Cited by 211
Rational Cancer Treatment Combinations: An Urgent Clinical Need
Boshuizen, J., & Peeper, D. S. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.031 · Cited by 210
Pennell, N. A., Neal, J. W., Chaft, J. E., Azzoli, C. G., Jänne, P. A., Govindan, R., Evans, T. L., Costa, D. B., Wakelee, H. A., Heist, R. S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00131 · Cited by 210
Fucà, G., Galli, G., Poggi, M., Lo Russo, G., Proto, C., Imbimbo, M., Ferrara, R., Zilembo, N., Ganzinelli, M., Sica, A., et al. (2019) · ESMO Open · doi:10.1136/esmoopen-2018-000457 · Cited by 209
Koneva, L. A., Zhang, Y., Virani, S., Hall, P. B., McHugh, J. B., Chepeha, D. B., Wolf, G. T., Carey, T. E., Rozek, L. S., & Sartor, M. A. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0153 · Cited by 209
Lamano, J. B., Lamano, J. B., Li, Y. D., DiDomenico, J. D., Choy, W., Veliceasa, D., Oyon, D. E., Fakurnejad, S., Ampie, L., Kesavabhotla, K., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2402 · Cited by 209
El Osta, B., Hu, F., Sadek, R., Chintalapally, R., & Tang, S.-C. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.09.002 · Cited by 209
Cho, J. Y., Kim, J., Lee, J. S., Kim, Y. J., Kim, S. H., Lee, Y. J., Cho, Y.-J., Yoon, H. I., Lee, J. H., Lee, C.-T., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.09.015 · Cited by 208
Memon, D., Schoenfeld, A. J., Ye, D., Fromm, G., Rizvi, H., Zhang, X., Keddar, M. R., Mathew, D., Yoo, K. J., Qiu, J., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.013 · Cited by 207
Squamous cell lung cancer: Current landscape and future therapeutic options
Lau, S. C. M., Pan, Y., Velcheti, V., & Wong, K. K. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.09.018 · Cited by 207
Fang, W., Ma, Y., Yin, J. C., Hong, S., Zhou, H., Wang, A., Wang, F., Bao, H., Wu, X., Yang, Y., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0585 · Cited by 207
Zhang, M., Yang, W., Wang, P., Deng, Y., Dong, Y.-T., Liu, F.-F., Huang, R., Zhang, P., Duan, Y.-Q., Liu, X.-D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19973-6 · Cited by 207
Immune checkpoint inhibitors: The linchpins of modern immunotherapy
Wilky, B. A. (2019) · Immunological Reviews · doi:10.1111/imr.12766 · Cited by 206
Applications of single-cell and bulk RNA sequencing in onco-immunology
Kuksin, M., Morel, D., Aglave, M., Danlos, F., Marabelle, A., Zinovyev, A. Y., Gautheret, D., & Verlingue, L. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.005 · Cited by 208
Hsu, P.-C., Jablons, D. M., Yang, C.-T., & You, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153821 · Cited by 205
Kim, K. H., Cho, J., Ku, B. M., Koh, J., Sun, J.-M., Lee, S.-H., Ahn, J. S., Cheon, J., Min, Y. J., Park, S.-H., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1449 · Cited by 205
“Clin Cancer Res; 25(7) April 1, 2019 2144”
BackgroundInfluentialDual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
Cheng, W., Kang, K., Zhao, A., & Wu, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01581-2 · Cited by 204
Treatment after progression in the era of immunotherapy
Billan, S., Kaidar-Person, O., & Gil, Z. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30328-4 · Cited by 204
Precision Management of Advanced Non–Small Cell Lung Cancer
Yang, C.-Y., Yang, J. C.-H., & Yang, P.-C. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-051718-013524 · Cited by 203
Grangeon, M., Tomasini, P., Chaleat, S., Jeanson, A., Souquet-Bressand, M., Khobta, N., Bermudez, J., Trigui, Y., Greillier, L., Blanchon, M., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.10.002 · Cited by 203
Huang, J., Xu, B., Mo, H., Zhang, W., Chen, X., Wu, D., Qu, D., Wang, X., Lan, B., Yang, B., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2439 · Cited by 203
Early Use of Systemic Corticosteroids in Patients with Advanced NSCLC Treated with Nivolumab
Scott, S. C., & Pennell, N. A. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.06.004 · Cited by 202
Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
Thomas, R., Al-Khadairi, G., & Decock, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.600573 · Cited by 202
Heymann, J. J., Bulman, W. A., Swinarski, D., Pagan, C. A., Crapanzano, J. P., Haghighi, M., Fazlollahi, L., Stoopler, M. B., Sonett, J. R., Sacher, A. G., et al. (2017) · Cancer Cytopathology · doi:10.1002/cncy.21937 · Cited by 202
Immune microenvironment composition in non‐small cell lung cancer and its association with survival
Tamminga, M., Hiltermann, T. J. N., Schuuring, E., Timens, W., Fehrmann, R. S., & Groen, H. J. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1142 · Cited by 201
Lung cancer in never smokers—the East Asian experience
Zhou, F., & Zhou, C. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.05.14 · Cited by 201
The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
Franzin, R., Netti, G. S., Spadaccino, F., Porta, C., Gesualdo, L., Stallone, G., Castellano, G., & Ranieri, E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.574271 · Cited by 201
Limagne, E., Richard, C., Thibaudin, M., Fumet, J.-D., Truntzer, C., Lagrange, A., Favier, L., Coudert, B., & Ghiringhelli, F. (2019) · OncoImmunology · doi:10.1080/2162402x.2018.1564505 · Cited by 201
Brunnström, H., Johansson, A., Westbom-Fremer, S., Backman, M., Djureinovic, D., Patthey, A., Isaksson-Mettävainio, M., Gulyas, M., & Micke, P. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.59 · Cited by 200
Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?
Hofman, P., Heeke, S., Alix-Panabières, C., & Pantel, K. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz196 · Cited by 200
Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
Li, X., Cheng, Y., Zhang, M., Yan, J., Li, L., Fu, X., Zhang, X., Chang, Y., Sun, Z., Yu, H., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0559-7 · Cited by 200
Clinical and translational advances in esophageal squamous cell carcinoma
(2019) · Advances in Cancer Research · doi:10.1016/bs.acr.2019.05.004 · Cited by 200
Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy
Ai, L., Chen, J., Yan, H., He, Q., Luo, P., Xu, Z., & Yang, X. (2020) · Drug Design, Development and Therapy · doi:10.2147/dddt.s267433 · Cited by 199
Borghaei, H., Langer, C. J., Gadgeel, S., Papadimitrakopoulou, V. A., Patnaik, A., Powell, S. F., Gentzler, R. D., Martins, R. G., Stevenson, J. P., Jalal, S. I., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.08.004 · Cited by 199
Ilié, M., Szafer-Glusman, E., Hofman, V., Chamorey, E., Lalvée, S., Selva, E., Leroy, S., Marquette, C.-H., Kowanetz, M., Hedge, P., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx636 · Cited by 199
Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment
Reda, M., Ngamcherdtrakul, W., Nelson, M. A., Siriwon, N., Wang, R., Zaidan, H. Y., Bejan, D. S., Reda, S., Hoang, N. H., Crumrine, N. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31926-9 · Cited by 198
Metabolism in tumor microenvironment: Implications for cancer immunotherapy
Shi, R., Tang, Y., & Miao, H. (2020) · MedComm · doi:10.1002/mco2.6 · Cited by 198
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
New clinical trial design in precision medicine: discovery, development and direction
Duan, X.-P., Qin, B.-D., Jiao, X.-D., Liu, K., Wang, Z., & Zang, Y.-S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01760-0 · Cited by 197
Adra, N., Einhorn, L. H., Althouse, S. K., Ammakkanavar, N. R., Musapatika, D., Albany, C., Vaughn, D., & Hanna, N. H. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx680 · Cited by 196
“This might have been a short interval given our understanding that the immune checkpoint inhibitors have a median time to response of 2 months [8, 10].”
BackgroundHellmann, M. D., Callahan, M. K., Awad, M. M., Calvo, E., Ascierto, P. A., Atmaca, A., Rizvi, N. A., Hirsch, F. R., Selvaggi, G., Szustakowski, J. D., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.011 · Cited by 196
Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
Arora, S., Velichinskii, R., Lesh, R. W., Ali, U., Kubiak, M., Bansal, P., Borghaei, H., Edelman, M. J., & Boumber, Y. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01051-z · Cited by 196
Kaira, K., Higuchi, T., Naruse, I., Arisaka, Y., Tokue, A., Altan, B., Suda, S., Mogi, A., Shimizu, K., Sunaga, N., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3806-1 · Cited by 195
KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition
Adderley, H., Blackhall, F. H., & Lindsay, C. R. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.02.049 · Cited by 195
Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases
Tison, A., Garaud, S., Chiche, L., Cornec, D., & Kostine, M. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00841-0 · Cited by 195
Corticosteroids and Cancer Immunotherapy
Goodman, R. S., Johnson, D. B., & Balko, J. M. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3181 · Cited by 197
Characterization of KRAS Mutation Subtypes in Non–small Cell Lung Cancer
Judd, J., Abdel Karim, N., Khan, H., Naqash, A. R., Baca, Y., Xiu, J., VanderWalde, A. M., Mamdani, H., Raez, L. E., Nagasaka, M., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0201 · Cited by 194
Mu, W., Tunali, I., Gray, J. E., Qi, J., Schabath, M. B., & Gillies, R. J. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04625-9 · Cited by 194
Johnson, D. H., Zobniw, C. M., Trinh, V. A., Ma, J., Bassett, R. L., Abdel-Wahab, N., Anderson, J., Davis, J. E., Joseph, J., Uemura, M., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0412-0 · Cited by 194
Sugawara, S., Lee, J.-S., Kang, J.-H., Kim, H. R., Inui, N., Hida, T., Lee, K. H., Yoshida, T., Tanaka, H., Yang, C.-T., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.06.004 · Cited by 193
Heist, R. S., Guarino, M. J., Masters, G., Purcell, W. T., Starodub, A. N., Horn, L., Scheff, R. J., Bardia, A., Messersmith, W. A., Berlin, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1894 · Cited by 193
Manohar, S., Kompotiatis, P., Thongprayoon, C., Cheungpasitporn, W., Herrmann, J., & Herrmann, S. M. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy105 · Cited by 193
Pawelczyk, K., Piotrowska, A., Ciesielska, U., Jablonska, K., Glatzel-Plucinska, N., Grzegrzolka, J., Podhorska-Okolow, M., Dziegiel, P., & Nowinska, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040824 · Cited by 192
“The estimation of PD-L1 expression was performed using the Tumor Proportion Score (TPS) that is applied routinely in diagnostic settings [4,27,28].”
MethodSex- and Gender-Based Pharmacological Response to Drugs
Mauvais-Jarvis, F., Berthold, H. K., Campesi, I., Carrero, J.-J., Dhakal, S., Franconi, F., Gouni-Berthold, I., Heiman, M. L., Kautzky-Willer, A., Klein, S. L., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000206 · Cited by 192
Jia, W., Gao, Q., Han, A., Zhu, H., & Yu, J. (2019) · Cancer Biology & Medicine · doi:10.20892/j.issn.2095-3941.2019.0144 · Cited by 192
Early detection of lung cancer biomarkers through biosensor technology: A review
Roointan, A., Ahmad Mir, T., Ibrahim Wani, S., Mati-ur-Rehman, Hussain, K. K., Ahmed, B., Abrahim, S., Savardashtaki, A., Gandomani, G., Gandomani, M., et al. (2019) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2018.10.017 · Cited by 192
Sun, L., Zhang, L., Yu, J., Zhang, Y., Pang, X., Ma, C., Shen, M., Ruan, S., Wasan, H. S., & Qiu, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-58674-4 · Cited by 192
“Except for twenty-three studies, the remaining studies (Barlesi 2018; Bellmunt 2017; Brahmer 2015; Cohen 2018; Fehrenbacher 2016; Fehrenbacher 2018; Ferris 2016; Gandhi 2018; Herbst 2016; Horn 2018; Reck 2016; Socinski 2018).”
BackgroundInfluentialDefining and Understanding Adaptive Resistance in Cancer Immunotherapy
Kim, T. K., Herbst, R. S., & Chen, L. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.05.001 · Cited by 192
“Therefore, the populations studied also included TIME type IV patients and do not accurately predict real primary resistance [34, 36, 37, 39].”
BackgroundChowdhury, P. S., Chamoto, K., & Honjo, T. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12708 · Cited by 191
Gong, J., Le, T. Q., Massarelli, E., Hendifar, A. E., & Tuli, R. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0361-7 · Cited by 191
Current state of immunotherapy for non-small cell lung cancer
Malhotra, J., Jabbour, S. K., & Aisner, J. (2007) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.03.01 · Cited by 190
The Role of the Estrogen Pathway in the Tumor Microenvironment
Rothenberger, N., Somasundaram, A., & Stabile, L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020611 · Cited by 190
Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC
Kargl, J., Zhu, X., Zhang, H., Yang, G. H. Y., Friesen, T. J., Shipley, M., Maeda, D. Y., Zebala, J. A., McKay-Fleisch, J., Meredith, G., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.130850 · Cited by 190
Evolutionary patterns and research frontiers in neoadjuvant immunotherapy: a bibliometric analysis
Jiang, S., Liu, Y., Zheng, H., Zhang, L., Zhao, H., Sang, X., Xu, Y., & Lu, X. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000492 · Cited by 189
Donlon, N. E., Power, R., Hayes, C., Reynolds, J. V., & Lysaght, J. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.12.045 · Cited by 189
Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations
Mazieres, J., Cropet, C., Montané, L., Barlesi, F., Souquet, P. J., Quantin, X., Dubos-Arvis, C., Otto, J., Favier, L., Avrillon, V., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.022 · Cited by 189
Ravi, A., Hellmann, M. D., Arniella, M. B., Holton, M., Freeman, S. S., Naranbhai, V., Stewart, C., Leshchiner, I., Kim, J., Akiyama, Y., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01355-5 · Cited by 188
Self-citationLi, M., Liu, F., Zhang, F., Zhou, W., Jiang, X., Yang, Y., Qu, K., Wang, Y., Ma, Q., Wang, T., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-316039 · Cited by 188
Immune checkpoint inhibitors and elderly people: A review
Daste, A., Domblides, C., Gross-goupil, M., Chakiba, C., Quivy, A., Cochin, V., de Mones, E., Larmonier, N., Soubeyran, P., & Ravaud, A. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.044 · Cited by 188
Sun, F., Zhu, Q., Li, T., Saeed, M., Xu, Z., Zhong, F., Song, R., Huai, M., Zheng, M., Xie, C., et al. (2021) · Advanced Science · doi:10.1002/advs.202002746 · Cited by 188
Singh, M. P., Rai, S., Pandey, A., Singh, N. K., & Srivastava, S. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2019.10.013 · Cited by 146
Hong, L., Negrao, M. V., Dibaj, S. S., Chen, R., Reuben, A., Bohac, J. M., Liu, X., Skoulidis, F., Gay, C. M., Cascone, T., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.04.026 · Cited by 187
Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?
Qiao, M., Jiang, T., Liu, X., Mao, S., Zhou, F., Li, X., Zhao, C., Chen, X., Su, C., Ren, S., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.04.003 · Cited by 186
Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer
Atchley, W. T., Alvarez, C., Saxena-Beem, S., Schwartz, T. A., Ishizawar, R. C., Patel, K. P., & Rivera, M. P. (2021) · Chest · doi:10.1016/j.chest.2021.02.032 · Cited by 186
Perspectives on the Treatment of Malignant Pleural Mesothelioma
Janes, S. M., Alrifai, D., & Fennell, D. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmra1912719 · Cited by 186
Reck, M., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100273 · Cited by 186
Self-citationPowell, S. F., Rodríguez-Abreu, D., Langer, C. J., Tafreshi, A., Paz-Ares, L., Kopp, H.-G., Rodríguez-Cid, J., Kowalski, D. M., Cheng, Y., Kurata, T., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.06.020 · Cited by 186
Self-citationKomiya, T., & Huang, C. H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00423 · Cited by 186
Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer
Blumenthal, G. M., Bunn, P. A., Chaft, J. E., McCoach, C. E., Perez, E. A., Scagliotti, G. V., Carbone, D. P., Aerts, H. J. W. L., Aisner, D. L., Bergh, J., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.09.017 · Cited by 184
Ashrafi, A., Akter, Z., Modareszadeh, P., Modareszadeh, P., Berisha, E., Alemi, P. S., Chacon Castro, M. D. C., Deese, A. R., & Zhang, L. (2022) · Cancers · doi:10.3390/cancers14194562 · Cited by 183
Biomarkers of response to PD-1 pathway blockade
Li, H., van der Merwe, P. A., & Sivakumar, S. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01743-4 · Cited by 183
“In particular, a landmark phase III study in 2016, KEYNOTE-024, showed that non-small-cell lung cancer (NSCLC) patients expressing PD-L1 on over 50% of tumour cells experienced a longer progression-free survival and overall survival after treatment with pembrolizumab compared to platinum-based chemotherapy [18].”
Management of Brain Metastases in Non–Small-Cell Lung Cancer
Ernani, V., & Stinchcombe, T. E. (2019) · Journal of Oncology Practice · doi:10.1200/jop.19.00357 · Cited by 183
“Patients with untreated BMs were excluded from the previous trials of single-agent pembrolizumab.(14,17) A phase II trial investigated the efficacy of pembrolizumab in patients with BMs, and the observed RR was 33%.”
MethodImmune Checkpoint Inhibitors for Lung Cancer Treatment: A Review
Onoi, K., Chihara, Y., Uchino, J., Shimamoto, T., Morimoto, Y., Iwasaku, M., Kaneko, Y., Yamada, T., & Takayama, K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051362 · Cited by 183
“60) [15] upon platinum-based chemotherapy as first-line therapy in a PD-L1 ≥ 50% NSCLC without driver mutations, and was approved for the first time as first-line treatment for NSCLC.”
Barroso-Sousa, R., Keenan, T. E., Pernas, S., Exman, P., Jain, E., Garrido-Castro, A. C., Hughes, M., Bychkovsky, B., Umeton, R., Files, J. L., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3507 · Cited by 182
Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer
Gaynor, N., Crown, J., & Collins, D. M. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.016 · Cited by 182
Peng, X.-X., Yu, R., Wu, X., Wu, S.-Y., Pi, C., Chen, Z.-H., Zhang, X.-C., Gao, C.-Y., Shao, Y. W., Liu, L., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000376 · Cited by 182
Metadata
- Authors
- Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., O’Brien, M., Rao, S., Hotta, K., Leiby, M. A., Lubiniecki, G. M., Shentu, Y., Rangwala, R., & Brahmer, J. R.
- Affiliations
- The University of Sydney (AU)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-11-10
- Volume
- 375
- Issue
- 19
- Pages
- 1823-1833
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2527905628
- Cited by
- 10,089
- References
- 54
- Citations by year
- 2026: 584 · 2025: 750 · 2024: 913 · 2023: 1012 · 2022: 1108 · 2021: 1321 · 2020: 1324 · 2019: 1154 · 2018: 1132 · 2017: 724 · 2016: 46
- FWCI
- 548.62
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- QUT ePrints (Queensland University of Technology) (submittedVersion)
- Funders
- Health Research Board (ICORG-2016-1)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- pembrolizumab, PD-L1-positive non-small cell lung cancer, PD-1 inhibitors, immune checkpoint inhibitors, platinum-based chemotherapy, progression-free survival, overall survival, objective response rate, treatment-related adverse events, EGFR wild-type, immunotherapy versus chemotherapy, duration of response
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Survival Analysis, Platinum Compounds, Intention to Treat Analysis, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.